Table S4.

Univariate and multivariate analyses to identify clinical characteristics associated with the detection of CSF-tDNA

Characteristic assessed in univariate or multivariate analysis	Odds ratio (95% confidence interval)	P value
Univariate logistic regression
Sex, female vs. male	1.07 (0.23–4.92)	0.93
Recurrent, yes vs. no	1.91 (0.19–18.93)	0.58
Race
A vs. W	0.15 (0.01–1.92)	0.15
AA vs. W	1.79 (0.05–62.48)	0.75
ME vs. W	0.15 (0.01–1.92)	0.15
AA vs. A	11.67 (0.19–736)	0.25
ME vs. A	1.00 (0.04–27.27)	1
ME vs. AA	0.09 (0.001–5.40)	0.25
Hydrocephalus, yes vs. no	2.40 (0.25–23.24)	0.45
Tumor grade, III and IV vs I and II	20.57 (2.16–196)	0.01
Enhancing imaging, yes vs. no	6.57 (0.52–83.75)	0.15
Tumor location
Spinal vs. infratentorial	0.66 (0.13–3.27)	0.61
Supratentorial vs. infratentorial	7.29 (0.29–185)	0.23
Supratentorial vs. spinal	11.0 (0.44–276)	0.14
Abutting CSF space, yes vs. no	59.9 (2.14–1,669)	0.02
Sequencing method, panel vs. WES	19.0 (0.90–401)	0.06
Location, promoter vs. exon and splice site	6.03 (0.25–148)	0.27
Age	1.01 (0.98–1.04)	0.64
Symptom duration	0.98 (0.91–1.06)	0.63
Tumor size	1.01 (0.99–1.02)	0.41
CSF volume	0.98 (0.72–1.32)	0.88
Quantity of DNA in CSF	1.00 (1.00–1.01)	0.2
Mutant allele fraction in tumor	3.55 (0.04–298)	0.58
Multivariate logistic regression
Tumor grade, III and IV vs I and II	26.51 (1.45–485)	0.03
CSF space, yes vs. no	90.59 (1.07–7,670)	0.05

A, Asian; AA, African American; ME, Middle Eastern; panel, directed sequencing of codons 130–139 of IDH1; codons 126–155, 144–178, and 250–262 of IDH2; all coding exons of TP53; and the TERT promoter (Materials and Methods); W, white.